Press Сentre
Наши новости
ChemRar Group provides Russian scientists with access to one of the world's largest collections of chemical substances for in vitro screening. The collection contains more than 1.6 million compounds and more than 100 ready-made focused libraries for medicinal chemistry projects.
The development of domestic innovative drugs is one of the ...
15.12.2023
This year, a large number of Chinese guests - suppliers of pharmaceutical ingredients , equipment and materials - became noticeable. On the first day, two main blocks of topics were covered: ensuring the development of the innovative potential of the Russian pharmaceutical industry, lessons from the Pharma-2020 program and their importance for the ...
08.12.2023
Actualmente, ChemRar y la empresa mexicana «Distribuidora y Exportadora de Medicamentos, S.A. de C.V. (DIEMSA)» han acordado sobre el registro sanitario en México y los suministros posteriores al país de medicamentos rusos para la terapia de enfermedades oncológicas.
En particular, se trata del fármaco antitumoral SUNITINIB (pertenece a ...
08.12.2023
To ensure technological sovereignty, leading universities could become new “development institutions” that, based on technological entrepreneurship, will bridge the gap between science and industry in key areas.
Andrey Ivashchenko, Chairman of the Board of Directors of the ChemRar Group, Head of the Department of Innovative Pharmaceuticals, ...
01.12.2023
Over the past decade, domestic pharmaceuticals have made a huge leap. But even more ambitious goals are set for it in the Pharma-2030 Development Strategy. How the leading companies in the industry plan to achieve them was told to “RG” by the Chairman of the Board of Directors of the ChemRar Group, Doctor of Technical Sciences, Professor of the ...
16.11.2023
At the First Moscow State Medical University named after I.M. Sechenov began clinical trials of a drug for the treatment of depression and panic disorder. The medicine was developed by the ChemRar group of companies, a leading domestic developer and manufacturer of innovative drugs. To create a high-tech production of active pharmaceutical ...
26.10.2023
From September 11 to 15, the VI International Forum of Oncology and Radiotherapy “FOR LIFE” took place in Moscow. The event was supported by the Ministry of Health of the Russian Federation, the Ministry of Science and Higher Education of the Russian Federation, the Russian Academy of Sciences and leading scientific, medical, educational ...
18.09.2023
Chairman of the Board of Directors of the ChemRar Group Andrey Ivashchenko took part in the business program of the Biotechmed-2023 forum, where, at various sites, together with key industry leaders and top officials of federal and regional authorities, state corporations, development institutions, academic institutes and universities of Russia ...
18.09.2023
On July 31, 2023, as part of the design and educational intensive “Archipelag 2023” at the “Chelovek+” site, a meeting of the updated composition of the expert group “Business Climate Transformations” was held in the direction of “New types of entrepreneurial activities based on the introduction of advanced technologies” ( TDK NTI ) . The ...
01.08.2023
From July 27 to 28, the Economic and Humanitarian Forum took place in Saint Petersburg as part of the Second Russia–Africa Summit. ChemRar Group’s representatives led by Irina Yuryevna Tyrnova, Member of the Board of Directors and Head of Exports, took part in the business program of this Forum.
As part of the Forum, a working meeting was held ...
31.07.2023
Avineiro company of the ChemRar Group announces that it has received a registration certificate from the Russian Ministry of Health for the drug AVIANDR® for the treatment of anxiety disorders. The drug was developed with the support of the Russian Ministry of Industry and Trade and within the framework of the NTI Neuronet roadmap. The full ...
10.07.2023
Elpida, the Russian developer of ELPIDA®, an innovative eslulfavarinin-based drug against HIV, has reduced the price for this medicinal product by 15 %. This discount will help the Russian healthcare system provide therapy to a larger number of HIV-infected patients throughout the country without excessive costs.
The end-to-end production cycle ...
22.06.2023
Публикации в печатных и электронных СМИ
Видео
Фото
